Report: US Advisory Panelists for Yaz/Yasmin Study Had Financial Ties to Manufacturers

In Defective Drugs, Latest News by tmccoy

by: Gary Falkowitz, Esq.

The United States Food and Drug Administration (FDA) was formed to protect the United States citizens from dangerous products. Part of their responsibility is to assess the dangers of a product and determine whether to give any particular product access to the market place. Moreover, there are specific committees within the FDA with narrow responsibilities. One of those committees is the advisory committee. The advisory committee is designed to give the agency independent judgment on medical issues.

What if I told you that doctors, who were a part of the FDA advisory committee in recent studies on Yaz and Yasmin, had financial ties to the manufacturers of Yaz and Yasmin? You don’t have to believe me, it’s been confirmed. See article here.

Reportedly, at least four members of a key committee advising the FDA on the safety of certain birth control drugs, including Yaz and Yasmin, have had financial ties to its manufacturers, raising questions about the rigor with which the agency minimizes potential conflicts of interest. The committee met on December 8, 2011 to analyze the safety data of drospirenone, which is found in several branded oral contraceptive pills, including Yaz, Yasmin, Beyaz and Safyral (all made by Bayer) and generic pills.

While each of the advisers with ties to the manufacturers indicate that they fully disclosed their ties to the FDA, it only begs the question of whether the results of any of these studies, conducted by the FDA, are accurate.

Currently, there is litigation against the manufacturers of Yaz and Yasmin pertaining to the following injuries:

  • Blood clots;
  • Pulmonary Embolisms;
  • Deep Vein Thrombosis;
  • Strokes; and/or
  • Gallbladder Disease
Report: US Advisory Panelists for Yaz/Yasmin Study Had Financial Ties to Manufacturers was last modified: January 11th, 2012 by tmccoy